Cardiovascular · Lipid ManagementRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Colestipol Hydrochloride Supplement by Impax Labs

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 6:35:10 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of an ANDA for a supplement of Colestipol Hydrochloride by Impax Labs is significant as it may strengthen their market position in lipid management. Competitors should be vigilant as this could lead to shifts in market dynamics and require strategic responses. Regulatory context from FDA (FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract competitive pressures. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Cardiovascular · Lipid Management, 8 regulatory and 4 competitive items passed relevance filtering for Impax Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Dexmedetomidine Hydrochloride by Baxter Healthcare (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma. This approval may enhance Impax Labs' position in the lipid management market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL) (FDA). Entity match (impax labs); Regulatory pathway relevance (nda). The ANDA approval indicates compliance with FDA standards, which may influence future submissions and approvals in the lipid management category.

Key Risks

Elevated medium regulatory exposure for Impax Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could enable Impax Labs to capture additional market share, impacting revenue for competitors with similar lipid management products.
Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract competitive pressures.

What Would Change This Assessment

This becomes more urgent if Monitor for further details on the supplement's indications and any subsequent market entry timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (impax labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TETRACYCLINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (impax labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPHENIDATE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (impax labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DILTIAZEM HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Approval for Dexmedetomidine Hydrochloride by Baxter Healthcare
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Impax Labs
Colestipol Hydrochloride

Commercial impact

medium

This approval could enable Impax Labs to capture additional market share, impacting revenue for competitors with similar lipid management products.

Regulatory impact

medium

The ANDA approval indicates compliance with FDA standards, which may influence future submissions and approvals in the lipid management category.

What to watch

Monitor for further details on the supplement's indications and any subsequent market entry timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.